Question 1

What is IDEXX Laboratories's P/E ratio?

Accepted Answer

IDEXX Laboratories (IDXX) P/E ratio is 40.1× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for IDEXX Laboratories?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For IDEXX Laboratories specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is IDEXX Laboratories's P/E ratio high or low?

Accepted Answer

IDEXX Laboratories's P/E ratio of 40.1× is below its own 5-year average of 51.7× and above the sector median of 24.2×. That places the current reading at the 6th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is IDEXX Laboratories's historical P/E ratio range?

Accepted Answer

In the available daily series, IDEXX Laboratories (IDXX) P/E ratio has ranged from a low of 17.8× in 2009 to a high of 90.8× in 2021. The 5-year average is 51.7× and the 5-year median is 49.8×.

Question 7

What was IDEXX Laboratories's P/E ratio in 2025?

Accepted Answer

IDEXX Laboratories (IDXX) P/E ratio at the end of 2025 was 51.1×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does IDEXX Laboratories's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$54.2B	$1.06B	51.1×	+13.0×	Dec 31, 2025
2024	$33.8B	$888M	38.1×	-16.5×	Dec 31, 2024
2023	$46.1B	$845M	54.6×	+4.8×	Dec 31, 2023
2022	$33.8B	$679M	49.8×	-25.2×	Dec 31, 2022
2021	$55.9B	$745M	75.0×	+1.5×	Dec 31, 2021
2020	$42.7B	$582M	73.5×	+21.0×	Dec 31, 2020
2019	$22.4B	$428M	52.4×	+9.8×	Dec 31, 2019
2018	$16.1B	$377M	42.6×	-9.3×	Dec 31, 2018
2017	$13.7B	$263M	52.0×	+4.8×	Dec 31, 2017
2016	$10.5B	$222M	47.2×	+12.7×	Dec 31, 2016
2015	$6.62B	$192M	34.5×	-4.4×	Dec 31, 2015
2014	$7.08B	$182M	38.9×	+9.5×	Dec 31, 2014
2013	$5.53B	$188M	29.4×	+0.9×	Dec 31, 2013
2012	$5.08B	$178M	28.5×	+2.2×	Dec 31, 2012
2011	$4.25B	$162M	26.3×	-1.9×	Dec 31, 2011
2010	$3.98B	$141M	28.1×	+2.8×	Dec 31, 2010
2009	$3.1B	$122M	25.4×	+7.0×	Dec 31, 2009
2008	$2.13B	$116M	18.4×	-19.6×	Dec 31, 2008
2007	$3.57B	$94M	38.0×	+11.6×	Dec 31, 2007
2006	$2.47B	$93.7M	26.4×	-2.9×	Dec 31, 2006
2005	$2.29B	$78.3M	29.3×	+6.3×	Dec 31, 2005
2004	$1.8B	$78.3M	23.0×	-5.2×	Dec 31, 2004
2003	$1.61B	$57.1M	28.2×	+3.9×	Dec 31, 2003
2002	$1.1B	$45.4M	24.2×	—	Dec 31, 2002


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for IDEXX Laboratories (IDXX) 2002-2026

P/E Ratio daily chart for IDEXX Laboratories (IDXX)

Historical P/E Ratio for IDEXX Laboratories (IDXX) from 2002 to 2025

About P/E Ratio at IDEXX Laboratories (IDXX)

IDEXX Laboratories P/E Ratio by Year

IDEXX Laboratories P/E Ratio 2025: 51.1×

IDEXX Laboratories P/E Ratio 2024: 38.1×

IDEXX Laboratories P/E Ratio 2023: 54.6×

IDEXX Laboratories P/E Ratio 2022: 49.8×

IDEXX Laboratories P/E Ratio 2021: 75.0×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

IDEXX Laboratories (IDXX) Key Financials